What is Cebix?
Cebix is a clinical-stage biopharmaceutical company dedicated to the development of ERSATTA, a novel C-peptide replacement therapy. The company addresses a significant unmet medical need for patients with type 1 diabetes, who lack the C-peptide hormone typically secreted alongside insulin. By restoring physiological levels of this hormone, Cebix aims to treat and potentially reverse debilitating long-term complications such as diabetic neuropathy, nephropathy, and retinopathy. Operating from its headquarters in La Jolla, California, the firm leverages rigorous clinical trial data to validate its therapeutic approach, aiming to transform the standard of care for chronic diabetic conditions through innovative hormone replacement strategies.
How much funding has Cebix raised?
Cebix has raised a total of $49.2M across 2 funding rounds:
Unspecified
$16M
Private Equity
$33.2M
Unspecified (2010): $16M with participation from InterWest Partners, Sofinnova Ventures, and Thomas, McNerney and Partners
Private Equity (2012): $33.2M, investors not publicly disclosed
Key Investors in Cebix
InterWest Partners
InterWest Partners is a prominent venture capital firm with a long history of investing in early-stage life sciences and information technology companies.
Sofinnova Ventures
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations.
Thomas, McNerney and Partners
Thomas, McNerney & Partners is a health care venture firm focused on investing in innovative life science and medical technology companies at all stages of development, providing growth capital to advance clinical development.
What's next for Cebix?
With the recent infusion of capital, Cebix is well-positioned to accelerate its clinical development programs and refine its commercialization strategy. The company's trajectory suggests a focus on advancing ERSATTA through late-stage clinical trials, with the ultimate goal of regulatory approval and market entry. As the firm transitions from a research-heavy entity to a more mature clinical-stage organization, the strategic deployment of these funds will be critical in scaling operations and strengthening its intellectual property portfolio. Investors and industry analysts will be closely monitoring the company's progress in demonstrating the long-term efficacy of C-peptide therapy, which could redefine the therapeutic paradigm for millions of patients worldwide.
See full Cebix company page
